Literature DB >> 8543398

Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes.

S L Davies1, R Popert, M Coptcoat, I D Hickson, J R Masters.   

Abstract

Biopsies of superficial bladder cancer were analysed to study the relationship between response to epirubicin and the expression of the human topoisomerase II alpha and beta genes. Tissue samples were obtained prior to treatment and a marker tumour was left in the bladder. Transcript levels of both genes were generally lower in biopsies taken following treatment failure. Levels of topoisomerase II mRNA were uniformly lower in tumour tissue than in biopsies of normal tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543398     DOI: 10.1002/(SICI)1097-0215(19960103)65:1<63::AID-IJC11>3.0.CO;2-J

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

Review 1.  Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.

Authors:  Yousaf Ali; Shafida Abd Hamid
Journal:  Tumour Biol       Date:  2015-10-20

2.  DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.

Authors:  S Withoff; A G van der Zee; S de Jong; H Hollema; E F Smit; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

3.  The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer.

Authors:  Lei Liu; Li-Min Mu; Yan Yan; Jia-Shuan Wu; Ying-Jie Hu; Ying-Zi Bu; Jing-Ying Zhang; Rui Liu; Xue-Qi Li; Wan-Liang Lu
Journal:  Int J Nanomedicine       Date:  2017-06-01

4.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Authors:  T A Järvinen; K Holli; T Kuukasjärvi; J J Isola
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.